Stock Quote
Stock Chart
Data Provided by Refinitiv. Minimum 15 minutes delayed.
MENU 
'
'
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
| Date Requested | Closing Price | Volume | Split Adjustment Factor | Open Price | Day High | Day Low |
|---|---|---|---|---|---|---|
| April 15, 2024 | $15.46 | 2,523,949 | 1:1 | $16.71 | $16.71 | $15.44 |
| April 16, 2024 | $14.65 | 1,932,544 | 1:1 | $15.40 | $15.40 | $14.39 |
| April 17, 2024 | $14.08 | 1,360,922 | 1:1 | $15.10 | $15.22 | $13.90 |
| April 18, 2024 | $14.44 | 1,489,147 | 1:1 | $14.11 | $14.60 | $13.64 |
NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
| Firm | Analyst |
|---|---|
|
Barclays
|
Peter Lawson, D. Phil. |
|
H.C. Wainwright & Co
|
Robert Burns |
|
J.P. Morgan
|
Eric W. Joseph, Ph.D. |
|
Morgan Stanley & Co. LLC
|
Terence C Flynn, Ph.D. |
|
Needham & Co.
|
Gil Blum, Ph.D. |
|
Oppenheimer
|
Matthew Biegler |
|
RBC Capital Markets
|
Gregory Renza, M.D. |
|
Robert W. Baird & Co
|
Joel Beatty, M.D., C.F.A. |
|
Stifel
|
Stephen D. Willey |
|
SVB Leerink
|
Christopher Liu, Pharm.D. |
|
Piper Sandler
|
Joseph M. Catanzaro, Ph.D. |
|
Wells Fargo Securities, LLC
|
Derek C. Archila |
Nurix Therapeutics, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Nurix Therapeutics, Inc. 's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Nurix Therapeutics, Inc. or its management. Nurix Therapeutics, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.